2019
Randomized phase II trial of exercise, metformin, or both on metabolic biomarkers in colorectal and breast cancer survivors
Meyerhardt JA, Irwin ML, Jones LW, Zhang S, Campbell N, Brown JC, Pollak M, Sorrentino A, Cartmel B, Harrigan M, Tolaney SM, Winer E, Ng K, Abrams T, Fuchs CS, Sanft T, Douglas PS, Hu F, Ligibel JA. Randomized phase II trial of exercise, metformin, or both on metabolic biomarkers in colorectal and breast cancer survivors. JNCI Cancer Spectrum 2019, 4: pkz096. PMID: 32090192, PMCID: PMC7025659, DOI: 10.1093/jncics/pkz096.Peer-Reviewed Original ResearchBreast cancer survivorsPhase II trialCancer survivorsControl armII trialInsulin levelsRandomized phase II trialInsulin-like growth factor-1Insulin-like growth factorHomeostatic model assessmentCombination of exerciseSignificant weight lossGrowth factor-1Combination armMetformin useSecondary outcomesStandard therapyPrimary outcomeIntervention armInsulin resistanceDisease outcomeModality interventionsAnthropometric measurementsMetabolic markersMetabolic biomarkers
2013
Weight Loss Intervention for Breast Cancer Survivors: A Systematic Review
Playdon M, Thomas G, Sanft T, Harrigan M, Ligibel J, Irwin M. Weight Loss Intervention for Breast Cancer Survivors: A Systematic Review. Current Breast Cancer Reports 2013, 5: 222-246. PMID: 26605003, PMCID: PMC4655116, DOI: 10.1007/s12609-013-0113-0.Peer-Reviewed Original ResearchWeight loss interventionBreast cancer survivorsMeaningful weight lossLoss interventionCancer survivorsWeight lossWeight loss intervention trialLong-term weight maintenanceCardiovascular risk factorsSuccessful weight lossBreast cancer recurrenceSmall study sample sizesBreast cancer prognosisSignificant weight lossBreast cancer diagnosisWeight regainPrimary outcomeWeight maintenanceIntervention trialsInterventional studyRisk factorsCancer recurrenceBreast cancerStudy sample sizePhysical activity